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1. Introduction 
Cancer of prostate is one of the very common diseases of ageing men with incidence rises up 
40% over the age of 75-80 years. It has also been noticed recently, that incidences of prostate 
cancers are on increase specially in many developing countries mainly because of long 
survival time due to better health care facilities available now-a-days and also due to 
changes in lifestyles of population of these countries. As compared with white men, black 
men have a 40% higher risk of the disease and twice the rate of death. The mortality due to 
prostate cancer has steadily declined for a decade, and it decreased by 4% per year between 
1999 and 2003. This decrease may be attributable to several factors, including earlier 
detection of cancer and improved local and possibly systemic treatment [1]. Thanks to the 
recent advancements in diagnostic tools, more and more patients are being diagnosed with 
potentially curable localized prostate cancer at a time where radical local treatment is 
deemed to be appropriate. For disease that is likely confined to the prostate and the 
immediate surrounding area, surgery, external beam radiation (EBRT) and seed 
implantation are the primary treatment options. In recent years, seed implantation has 
become more popular as a treatment option as it is simpler, less traumatic and the duration 
of relief is comparable. It has been estimated that up to 50% of patients with early stage 
prostate cancer are now receiving ultra sound guided seed implantation [2]. 
2. Historical background 
Seed implantation for prostate cancer began in 1911. Louis Pasteur suggested that surgical 
insertion of radium seed into the prostate may eradicate this malignancy [3]. A number of 
techniques were subsequently used with limited success. In the 1960s, Drs. Scardino and 
Carlton at Baylor College of Medicine, Houston, reintroduced permanent prostate 
brachytherapy using 198Au interstitial implantation in combination with external beam 
radiation therapy (EBRT)[4].  
At about the same time, Dr. Whitmore and colleagues at Memorial Sloan Kettering Cancer 
Center (MSKCC) also began to insert 125I seeds through an open incision as a sole treatment 
[5]. Unfortunately, these early techniques did not allow for clear visualization of the seeds as 
they were being inserted into the prostate and, as a result, there was often poor dose 
coverage of the prostate gland. However, some important information was obtained from 
these early seed implantation approaches. Local control was better in patients who received 
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high-quality implants and who had low-grade and early-stage cancer. The subsequent 
development of the transperineal, ultrasound guided approach provided a means to more 
accurately place seeds and thereby improve dose coverage. In the 1980s, several 
investigators were exploring new brachytherapy approaches to the treatment of prostate 
cancer. Drs. Syed and Puthawala pioneered a temporary seed technique of placing the 
needles while visualizing them through an open laparotomy [6]. In 1983, Dr. Holm 
introduced the use of transrectal ultrasound to visualize the permanent placement of 125I 
seeds via needles inserted through the perineum directly into the prostate[7]. Drs Blasko 
and Ragde [8] began the first transperineal ultrasound-guided approach in the United 
States. The transperineal ultrasound-guided, approach resulted in increased accuracy of 
seed placement and relatively even distribution of seeds throughout the prostate. This 
marked a major advance in prostate brachytherapy in that it allowed more precise planning 
of the implant prior to the procedure. These advances also significantly increased the 
accuracy of seed placement and insured that the prostate would receive the proper number, 
strength, and positioning of radioactive sources.  
The first transrectal ultrasound-guided, template-guided 125I implant procedure was carried 
out at the Seattle Prostate Institute in late 1985 and is now being practiced around the world. 
The original Seattle approach has been modified and improved several times since the 
original implants. As this procedure has become more popular, many technical 
improvements have been added to improve the consistency and quality of the procedure. 
The availability of better imaging techniques such as transrectal ultrasound, fluoroscopy, 
high quality CT scan, etc. have now made permanent prostate implants much more refined. 
Today, the implant is planned prior to the procedure either on the day of or several weeks 
prior to the implant. Typically, the implant is completed in a 45-90 minute outpatient 
procedure under spinal anesthesia or light general anesthesia [8]. 
In addition to the availability of loose sealed radioactive sources, seeds incorporating 
radionuclides such as 125I ,103Pd and 131Cs are now available in continuous strand form, 
increasing the likelihood that the seeds will remain in place after implantation. About 60-140 
radioactive seeds encompassing the entire prostate gland are used to eradicate the tumor. 
While slight differences in technique are expected to grow as more and more physicians 
perform this procedure and as more technical advances are made, the basic approach is 
quite similar and it remains to be determined whether any single technique will prove 
superior in controlling the cancer. 
3. Selection of radionuclide 
Beginning in 1967, 125I became the first radioisotope sealed within a titanium capsule 
popularly known as seed. While its use continues to this day, many patients and doctors in 
recent years have chosen shorter half-life isotopes other than 125I such as 103Pd and 131Cs.  
Radionuclides used in the prostate radiotherapy are 125I, 103Pd or 131Cs. The radiation 
characteristics of these three isotopes are given in Table 1. The high energy (10-50 MeV) 
cyclotron produced 103Pd is not yet available in India. The reactor production of 131Cs is 
difficult due to low percentage abundance of 130Ba (~1%) in natural targets and the logistics 
and cost considerations of this isotope do not permit its use at present. On the other hand, 125I 
with its relatively longer half-life and suitable gamma energy coupled with ease of production 
is a cost effective isotope and can be easily produced by (n,γ) reaction of natural 124Xe gas in a 
special set up provided in the research reactors (DHRUVA) of BARC, Mumbai, India. The 
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production and processing procedures for 125I have been developed and regular production of 
this isotope has been commenced by Radiopharmaceuticals Division, BARC, Mumbai. 
The Indian pursuit of developing technology for 125I brachytherapy sources was driven 
mainly by three considerations, namely, (a) well-established and ease of reliable production 
of 125I in several GBq quantities in the research reactors in BARC, (b) need to provide 125I- 
brachytherapy sources at an affordable cost to meet the domestic needs, (c) help to ease 
reliance on import and to promote the beneficial use of 125I- brachytherapy sources in the 
country.  
 
Isotope T1/2 
Specific 
Activity 
(TBq/g) 
Mode of 
Decay 
Average 
Energy 
(keV) 
Dose 
Delivery
Total 
Dose 
Production methods 
125I 60d 650 
EC 
(100%) 
28.5 
90% in 
204 days
145 Gy
124Xe(n,)125Xe125I 
Nuclear Reactor 
103Pd 17d 2763 
EC 
(100%) 
21 
90% in 58 
days 
125 Gy
103Rh(p,n)103Pd 
Cyclotron 
131Cs 9 d 3808 
EC 
(100%) 
30.4 
90% in 33 
days 
115 Gy
130Ba(n,)131Ba131Cs 
Nuclear Reactor 
Table 1. Radiation Characteristics of radionuclides used in prostate seed implantation 
4. Source requirements  
The encapsulated source’s outer dimensions are ~ 4.75 mm length and 0.8mmdia. The active 
core is situated within the shell of the capsules, often of 50 micron thickness. Iodine belongs 
to the halogen group of elements which is highly reactive. Although several stable 
compounds of iodides are reported in the literature, most of them have a definite solubility 
in water/saline. The main challenge, therefore, is to develop a non-leachable source core 
containing 125I incorporated in a solid substrate at very high specific activity. Production of 
the source core in a highly reproducible manner within acceptable dimensional tolerances is 
yet another challenge. An innovative strategy has to be devised to develop the necessary 
technology for fabrication of 125I source core, capsules and encapsulation technique. 
Preparation of 125I-brachytherapy sources addresses the following main issues: 
a. Immobilization of 125I in a suitable solid matrix.  
b. Quality evaluation of the sources. 
c. Fabrication of titanium capsules of suitable dimensions. 
d. Hermetic Sealing of the capsules by Laser welding. 
e. Quality assurance of the encapsulated sources.  
5. Preparation of 
125
 I minature source cores  
Two types of source core are used for the preparation of 125I seed; namely  
 Rod/wire type sources 
 Spherical type sources 
Silver is chosen as the basic matrix for immobilization of iodine which functions both as the 
active support and as the x-ray marker. Iodine-125 can be used directly in its elemental 
form, or as iodide, iodate, hypoiodate, or other ionic forms, or in the form of compounds 
such as aliphatic or aromatic iodo labeled compounds. The choice of anion(s) depend on 
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the methodology intended to use. Owing to volatile nature of elemental iodine, iodide ions 
are used for source preparation. Iodine-125 as iodide may be physically trapped in or on the 
substrate, by adsorption, or may be chemically attached to it in some way. The radioactive 
source core should be of an overall size and dimensions to fit inside a conventional seed 
container suitable for encapsulation. The range of desired activity is about 0.3 to 4.0 mCi 
per seed. 
5.1 Preparation of rod/wire type source cores 
Silver wires of guranted purity of 3 mm length & 0.5mm dia are used to incorporate 
Iodine-125. The following methodologies were explored for preparing 125I-silver rod 
source core. 
1. Electrodeposition 
2. Physical & physico-chemical adsorption 
5.1.1 Electro deposition  
Anodic electro deposition of radio iodine (125I) was carried out in a quartz bath size [1.2 cm 
(dia.), 2.5 cm (ht)] with platinum cathode (1mm). The wires were arranged in the cell as 
shown in Fig.1. Various experimental parameters such as the current used, radioiodine 
concentration in the cell and time for deposition were optimized to obtain maximum activity 
on the silver wire. By this method, more than 85% of the initial radioactivity could be firmly 
deposited on the source at 20 µA current for 25-30 min duration on the silver wires. These 
sources with extremely good reproducibility and consistency with respect to activity 
content, could by this method [9].  
 
 
Fig. 1. Schematic diagram of the electro-deposition set-up. 
Cieszykowska et al.[10] have also developed an electrochemical method of depositing 125I 
form an electrolyte containing 0.01 M NaOH. In brief, 10 ml of solution containing 
appropriate amount of I-125 was taken in a platinum crucible which served as cathode. The 
cathode consists of a single silver bar of 3 mm long and 0.5 mm in diameter. The volume of 
the electrolyte used was 10 mL and the distance between the electrodes was about 20 mm. 
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The potential of the cell was kept at 233 mV. The electrodeposition was carried out under 
ultra violet radiation.  
5.1.2 Iodination of the silver rod 
Zhang et al. [11] have described a method of depositing 125I using chlorinated silver rod. In 
brief, the procedure involved coating a layer of AgCl on the silver rod of 3 mm long and 0.5 
mm in diameter. The activated silver rods were put into 4 mol/l nitric acid and heated for 5 
minutes. They were then put into a mixed solution of sodium hypochlorite and hydrochloric 
acid. The chlorinated silver rods were put in Na125I solution at pH > 6.5 to deposit required 
amount of 125I. 
5.1.3 Absorption of 
125
I on a ceramic matrix 
Han et al. [12] have described a method of depositing 125I using a ceramic rods. The ceramic 
rods of 3 mm long and 0.5 mm sizes were immersed in conc. HF solution for 4 hours, 
scratched with a specially made pin along the length at regular intervals to made miniature 
horizontal cavities of ~ 0.1 mm depth. they were then immersed aqueous AgNO3 solution to 
absorb the solution. Impregnation of 125I on to the treated rod was carried out by the 
controlled addition of Na125I solution at pH > 9 to deposit required amount of 125I. 
Extending this theme, Park et a1.[13] have investigated the possibility of adsorption of 125I 
on a Ag + Al2O3 rod as a carrier body. The adsorption capacity was more than 95% after 4 
hours at a volume of 50 μl containing about 5 mCi of 125I.  
5.1.4 Physico-chemical adsorption 
Our group have used a novel method to adsorb radioiodine(125I) on silver wires, by 
precoating the wires with palladium[14-15]. The experimental conditions such as amount of 
radioactivity, carrier concentration, reaction time, reaction temperature, reaction volume, 
pH of the reaction mixture, etc. were systematically optimized to achieve best results. More 
than 80% of the initial radioactivity could be firmly deposited on the source core. The 
sources with extremely good reproducibility and consistency with respect to activity content 
and other quality parameters could be produced. 
The microstructures of plain silver wire and palladium coated silver wires are shown in Fig. 
2 (a) and (b) respectively, indicating the presence of huge sites for sorption of iodine on 
palladium cated silver wires.  
 
 
(a)      (b) 
Fig. 2. (a) SEM of Plain Silver wire Fig. 2 (b) SEM of Palladium Coated Silver wire 
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5.1.5 Comparison of techniques 
The electrodeposition method of preparing 125I source core is a straight forward procedure 
and used by many commercial manufacturers of these sources. Quantitative firm and 
uniform deposition could be obtained by the optimized parameters, with low leaching of 
activity. However this method is labour intensive, require high skill and would be exposing 
personnel to long time to radiation. The electro deposition method is attractive only if 
automated system where radioactive iodine is electrodeposited on a long piece of silver wire 
of the required diameter and subsequently precision cut in to the required dimensions by 
remotely operated electro mechanical cutting devices, is available. 
The inherent drawbacks of absorption of 125I on a ceramic matrix and iodination of the 
silver rod, include a tedious time-consuming matrix preparation procedure, need for strict 
adherence to the operational protocol, and the requirement for well-trained, skilled 
operator.  
Chemisorption of 125I activity on the PdCl2 treated silver wire as more suitable for 
adsorption of 125I than plain silver wires in terms of quantitative adsorption and non-
leachability of 125I activity. The procedure is straightforward and easily performed. The 
workload to use this protocol is small. The incidence of serious error may be low. The mild 
experimental conditions of adsorption at neutral to alkaline pH facilitates the safe handling 
of high amounts of radioactivity for the preparation of therapeutic sources without the 
release of air activity. The stability of 125I on Pd coated silver wire is due to the formation of 
insoluble palladous iodide on the surface of the wire and accounts for low leachability. This 
procedure is routinely used by Radiopharmaceuticals Division, BARC, Mumbai. Fig. 3 
depicts the laboratory used for the regular production of 125I source core. 
 
 
Fig. 3. Laboratory for the production of 125I source core 
5.2 Preparation of spherical type source cores 
A linear assembly of six alumina microspheres or six palladium coated silver spheres of 0.5 
mm() were used for making spherical seed sources. 
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5.2.1 Alumina microspheres 
A mixture of pre-cooled (5°C) solution of hexamethylenetetraamine and urea (3 M) with 
aluminum nitrate solution was dispersed as droplets into hot oil to bring about the 
formation of aluminium hydroxide in to solid gel sphere form. The spheres were dried in an 
air oven at 100°C and heat treated at 700°C for 5 h in a furnace to obtain alumina spheres. 
Spheres of uniform sizes were selected by passing through a 600 m mesh. The 
experimental conditions such as amount of radioactivity, carrier concentration, reaction 
time, reaction temperature, reaction volume etc. were systematically optimised. By this 
method, more than 95% of the initial radioactivity could be firmly deposited on the source 
core and 0.6-0.8 mCi of radioiodine could be adsorbed on the alumina microsphere [9].  
5.2.2 Metallic microspheres 
Silver beads of dimension of 0.5 mm() were pre-coated with palladium for the 
incorporation of radioiodine (125I). The experimental conditions such as amount of 
radioactivity, carrier concentration, reaction time, reaction temperature, reaction volume, 
pH of the reaction mixture, etc. were systematically optimized [16]. By this method, more 
than 83 % of the initial radioactivity could be irreversibly adsorbed on the palladium coated 
on the source core and radioactive sources in the range of 20-251 MBq ( 0.5-0.6 mCi) can be 
prepared. The sources with extremely good reproducibility and consistency w.r.t. activity 
content and other quality parameters could be produced. All the sources were measured 
with calibrated ionization chambers and seed strength was quoted with an overall 
uncertainty of  10%.  
5.2.3 Comparison of techniques 
The physicochemical adsorption of radioiodine on alumina microspheres is easy and also 
less expensive. Quantitative adsorption of activity on the spheres is possible by using 
radioactive iodine in iodate (IO−3) form. However, it was found that the percentage 
leachability of radioactivity from the spheres was more than desirable. Further 
developments are needed to assess the potential of this approach on a reliable and 
continuous basis. 
The physicochemical adsorption of Pd-silver microspheres is easy and 125I-beads could be 
prepared in a nonleachable form. The radioactive sources upto ~111MBq (3 mCi) activity 
can be prepared by arranging six individual beads in a well-arranged geometry.  
6. Fabrication of titanium capsules 
The capsule matrix should have chemical compatibility with the source core which will be 
encapsulated inside. The capsule material need to be of low atomic weight so that it would 
attenuate radiation to a minimum extent. Titanium's unique combination of attributes such 
as light weight, high strength to weight ratio, corrosion resistance, amenability for easy 
welding, biocompatibility, and durability in extreme environments make it an excellent 
material for capsule fabrication. Titanium is used extensively for medical and dental 
implants because it is biocompatible with the human body. It is completely inert and 
immune to corrosion by all fluids and tissues of the body, making it ideal for encapsulation. 
The wall thickness of the capsule should be adequate to provide requisite mechanical 
strength to retain the source core, in order to reduce the risk of radioactive contamination in 
www.intechopen.com
 
Prostate Cancer – Original Scientific Reports and Case Studies 
 
66
the event of source rupture during handling. At the same time it should not be too thick to 
attenuate the radiation emanating from the source. The wall thickness of the capsule is 
configured to provide adequate mechanical strength as well as required radiation output. 
About 0.05 mm thick titanium tubes is sufficient to allow gamma rays and low energy X-
rays to pass through for providing therapeutic effect. It is preferred that the capsule have an 
open end and a closed end. The capsule is preferably sealed with a suitable end cap using 
techniques such as laser/electron beam welding. 
The titanium Capsules of the required dimensions 4.75mm(l) x 0.8 mm() x 0.05mm(t) along 
with suitable caps(lids) of 0.8mm() are generally used. Fig.4 shows the cross-sectional view 
of titanium encapsulated wire source and microspheres. 
 
 
 Microspheres     Rod type 
Fig. 4. Cross sectional view of encapsulated 125I- sources. 
7. Laser welding of titanium capsules  
The welding of capsules containing radioactive sources requires that the following 
conditions are met: 
 The welding has to be carried out in a well ventilated shielded enclosure  
 The process of welding should be feasible in a remotely operated system. 
 The welding should not change the geometry of the capsules. 
 Loss of activity during the welding should be minimum(minimum heat input to the 
active source) 
 Efficiency of welding should be such that there should not be leakage of activity after 
welding.( Welding should cause less porosity) 
The activities of the 125I rods/spheres were measured and the sources with activity within 
 5 % of the targeted activity (generally 111 MBq/source) were segregated and used for 
encapsulation. The rods were inserted individually into the titanium capsule followed by 
placement of a cap over it with the aid of magnifying glass. The source loading procedure 
adapted in radiopharmaceuticals Division of Bhabha Atomic Research Center is depicted 
in Fig.5. 
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Fig. 5. Loading of 125I source core inside the capsules 
Although the tungsten inert gas (TIG) process is the most common method for welding SS 
capsules, this is not suited to our type of application.TIG welding cause molten titanium to 
flow down and the weld was observed to be porous. The most likely cause of porosity is the 
trapping of gas bubbles between dendrites during solidification and presence of hydrogen 
from moisture in the arc environment. This resulted in the leakage of radioactivity from the 
welded capsules significantly higher than the prescribed limit. Hence an alternative method 
of welding is to be adopted. 
In order to circumvent these problems, a pulsed laser welding system was used for the 
encapsulation of capsules. This system consists of a laser head, power supply unit, chiller 
unit and welding system. As the welding is carried out in pulses, the heat input to the 125I 
source is reduced. The Nd:YAG laser installed inside the fume-hood in our laboratory is 
shown in the Fig.6. The output of the laser is taken through the ports and it is connected to 
the welding head using optical fiber.  
 
 
Fig. 6. Laser Welding System 
www.intechopen.com
 
Prostate Cancer – Original Scientific Reports and Case Studies 
 
68
Major advantages of laser beam welding are low welding stresses, low risk of distortion, 
creation of minimal heat affected zone with minimal 125I contamination and capability of 
welding of varying mass that allows hermetic sealing of Ti capsules. Nd:YAG pulsed lasers 
have the ability to weld hard materials like Ti and produce an aesthetic weld with high 
depth/width ratio free from any weld buildup that eliminates many secondary operations 
such as grinding or honing. It has also high welding speed, good reproducibility, flexibility 
and the process can be easily be remotized and automated. Due to the extreme reactivity of 
titanium metal, it is essential to shield the molten pool and the hot metal from contact with 
air. Argon is used as inert gas protection.  
Prior to welding, the welding parameters such as energy of laser pulse, frequency, pulse 
duration and rotational speed of sample are systematically optimized to obtain quality 
welds with negligible leakage. The laser-welding operations were carried out remotely 
using PC-based controlled system. Fig. 7 depicts a typical welded 125I- seed. 
 
 
Fig. 7. Encapsulated 125I- brachytherapy sources 
The metallography test of welded capsules was carried out by optical metallography (The 
metallograph of a welded source is shown in Fig. 8.  
 
 
Fig. 8. Optical micrograph (50 times magnified) of a welded capsule. 
The penetration depth in the samples was evaluated by Scanning Electron 
Microscopy(SEM). The SEM micrograph is depicted in Fig. 9. The penetration depth was 
found to be ~ 2-3 times the wall thickness of the capsules. The welded samples showed high 
integrity and superior metallurgical quality. 
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Fig. 9. SEM of welded capsule 
8. Quality control of sealed sources 
Quality is “the degree to which a set of inherent characteristics fulfils requirements.” 
Control is “the need or expectation that is stated, generally implied or obligatory.” Iodine-
125 sources produced are subjected to numerous checks obligatory by regulatory 
authorities. The emphasis given is on the physical and chemical aspects. The schematic 
diagrm of an assembly of laser welded 125I seed is shown in Fig. 10. 
 
 
 
 
Fig. 10. Assembly of laser welded 125I seed 
8.1 Source strength measurement 
The estimation of source activity/ strength for the seed was carried out by using a calibrated 
well-type ionization chambers. The charge collected per unit time by keeping the source at 
the position of peak response in the well chamber was multiplied by the calibration factor to 
estimate the activity content of source. The factor recommended by AAPM for converting 
the strength of 125I-seeds from apparent activity (mCi) to source strength (i.e. air kerma 
strength) is 1.27 mGy/h-m2 per mCi (irrespective of internal construction of the source) and 
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the same was used as a reference for the studies carried out at our end. A source calibration 
accuracy of ~ 3% relative to existing air kerma standards seems reasonable. The radiation 
equipment should not be used whenever the level is exceeded. 
8.2 Leachability 
Source cores ( Un-encapsulated) were immersed in 100 mL of still distilled water at ambient 
temperature for 48 hours. At the end of 48 hours, the total leached out radioactivity was 
assayed to determine the leachability of bare sources should be less than 0.01% of the total 
seed activity. The physico-chemical adsorption method [14] adapted by us was found to 
achieve this limit and thus complied with regulatory norms.  
8.3 Swipe test 
The sealed sources are tested for surface contamination or presence of any loose activity by 
swiping the sources using alcohol immersed cotton wool and checking the radioactive 
content in a NaI(Tl) scintillation counter. When the activities detected in the swipe is less 
than 185 Bq, the sealed source capsule is considered to be contamination free. 
8.4 Uniformity of activity 
Uniformity of deposition of 125I activity was examined by autoradiography using a specially 
designed gadget (Fig. 11.) A circular disc [ 4.4 cm (), 1.4cm thick] made of brass with a 
central hole of 3mm diameter and 8 mm depth was taken and eight equidistant tunnels (45o 
angle between each successive tunnels) of uniform aperture were drilled through the central 
hole. One source was placed at a time in the central hole and autoradiographed 
simultaneously by wrapping a strip of photographic film all along the side of brass disc.  
 
 
 
Fig. 11. Gadget for Auto-radiography 
The film gets exposed from eight equidistant directions through the holes. The Optical 
density distribution of the exposed film at different angles was measured by B/W 
transmission densitometer. The variation in OD values at different positions should be ±10 
%. Sources prepared by the physico-chemical adsorption methodology [14] in our laboratory 
has variation within ± 5% (Fig.12). 
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Fig. 12. (a) Specially designed autoradiography gadget; b) developed autoradiography film 
of the sources. 
8.5 Leakage test  
It was mandatory to check all the sealed sources to ascertain leak tightness of the sealing. 
The following tests are performed on all the sources.  
Bubble test  
The fabricated sealed sources are placed in nearly boiling water kept in a glass beaker for 
about 2 minutes. Appearance of bubbles from the sealed sources indicates improper sealing 
and such sources are discarded.  
Pressure test  
The fabricated sealed sources are immersed in a closed glass container containing ethylene 
glycol and the pressure inside the chamber is reduced to 100 mm of Hg. Any leak from the 
sources is shown by a string of bubbles, and such sources are rejected.  
8.6 Immersion test 
One sealed source is immersed in 20 mL of water taken in a glass beaker and heated to 50oC 
for 5 hours. The source is removed, the water concentrated to 1mL and the activity released 
is estimated in a well type NaI(Tl) counter. Activity measuring 185 Bq /source is considered 
to be the limit for acceptance of leak tightness. When the activities detected in the immersion 
test of the sealed source is less than 185 Bq, the sealed source capsule is considered to be leak 
tight. 
The following steps should be taken during Quality Control of 125I seeds. 
i. The surface of each source must be checked regularly for visible damage. Sources with 
damaged surface must not be touched for wipe test. 
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ii. All quality control results must be documented. 
iii. For each type of test separate instrument should be used. 
iv. Ion chamber used for measuring activity should be used solely for that purpose only 
and should be kept separately. 
v. Swipe test should be carried out using a dedicated surface contamination detector 
which can easily show even the smallest amount of radioactive material. The table used 
for keeping the surface contamination detector must be separated from the source 
preparation laboratory. The instruments may get contaminated and must be 
decontaminated regularly. The verification of the absence of radiation in the surface 
contamination detector should be a routine task.  
9. Classification performance testing 
For use of radioactive seeds in interstitial applications, where sources of higher radioactive 
strength of the order of 30 GBq to 370 GBq and comprising of radiologically more hazardous 
and longer lived radionuclides such as 137Cs, 192 Ir etc. are used, the integrity of sources upto 
a temperature of 600ºC is necessarily evaluated. In case of 125I-seeds, the strength of a typical 
implant of 100 seeds is very low ( 1.85-3.7 GBq) as compared to the strength of 137Cs or 192 Ir 
sources. However, the volatile nature of iodine makes the source vulnerable to air borne 
release of radioactivity at higher temperature exposure conditions. In view of the low levels 
of radioactivity, low radiotoxicity and less risk of accidents or hazards associated with 125I -
seeds, the exemption for test at 600ºC seeds was sought from Atomic Energy Regulatory 
Board, India. 125I -seeds were tested upto 400°C, a temperature that was experimentally 
found to release the radioactivity within the permissible levels of 185 Bq. Release of 
radioactivity from sources after subjecting them to various classification performance 
evaluation tests was found to be well within the permissible level of 185 Bq and the source 
design was approved by Atomic Energy Regulatory Board, India under class C-43211. 
Classification performance testing of indigenous 125I-seeds was carried out for ensuring their 
safety in brachytheray applications [17] and following tests were performed. 
9.1 Temperature and thermal shock tests 
Sealed sources were tested for their integrity under extreme temperature as well as quick 
changes in temperature. Two sources are heated to of 400 ºC in a controlled manner and 
kept at this temperature for one hour. Two other sources are heated to 400 ºC for 15 minutes 
and then quenched to 20ºC. Two other sources are cooled to - 40 ºC and kept at this 
temperature for 20 minutes. All these sources are subjected to tests for leakage in hot water 
and surface contamination as described above. When the activities detected are less than 
185 Bq, the sealed source pass this test. 
9.2 Pressure test 
In order to assess the strength of the sources to withstand extreme pressures, two sealed 
sources are subjected to a pressure of 2 MPa. In a separate set-up, two sources are subjected 
to a vacuum of 25 kPa. After repeating two cycles of both these tests for 5 minutes, tests for 
leakage in hot water and surface contamination are carried out. When the activities detected 
in the swipe as well as in water are less than 185 Bq, the sealed sources were consider 
withstanding extreme pressures. 
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9.3 Impact test 
In order to evaluate the ability of the sealed source to withstand high impacts, a steel billet 
of 50 grams weight is dropped over the sealed sources from a height of one meter. The 
integrity the sealed source is then examined by visual examination as well as conducting 
leakage tests and surface contamination tests. If a wipe test or leakage tests detects less than 
185Bq (0.005 μCi) of removable radioactive material, the sealed sources are consider 
withstanding high impacts. 
10. Radiological safety 
In view of radioactive nature of 125I, safe and appropriate radioactive procedures should be 
adopted during the whole preparation process. Although gamma/X-ray emanating from 125I 
have little penetrating power, they are hazardous if 125I is ingested or inhaled. For this 
reason, it is recommended to wear protective clothing and safety glasses when working 
with 125I. Radiation monitoring of personnel should be accomplished with TLD dosimeters 
worn while working. The room or area used for the preparation of 125I sources must be 
posted with a sign having the words "Caution - Radioactive Materials". Ventilation of the 
source preparation laboratory should be sufficient to quickly reduce the presence of gaseous 
radioactive products. It is useful to locate a surveillance monitor in the source preparation 
laboratory which can give a warning signal if there is significant increase in the radiation 
level resulting from radioactive contamination on the work place. The sensitivity of the 
monitor should be easily adjustable. The ALARA principle should be observed with regard 
to the radiation exposure of the operating staff. Reduction of the dose during the 
preparation of 25I-brachytherapy sources can be achieved by a combination of the 
following principles: 
i. Reduce the time of exposure during handling of activity, as the total dose is 
proportional with time. Materials and equipment used for source preparation must be 
set ready. Procedures must be practiced with non-active, dummy material to gain 
experience.  
ii. Keep the distance as large as possible. Radioactive materials should not be touched by 
hand. It is recommended to use long forceps or tweezers to handle the source cores. The 
inverse square law is the most effective method of dose reduction. 
iii. Reduce the amount of radioactive materials handling as far as possible. Measures must 
be taken to reduce the exposure from the radioactive materials not used for source 
preparation. Each source must be subjected quality control separately, while any other 
source is stored in a shielded container and set aside at some distance. 
iv. Use the shielding material that is available. Examples are the shields at the preparation 
hood or movable shields besides the ion chamber. 
Radioactive sources cannot be left in the laboratory hood. All fabricated sources must be 
registered. The register must contain information on the activity on a given date and 
eventually the batch number and the results of the QC checks. The sources have to be locked 
away safely in a storage container. The radiation level at 1 m from the container surface 
should be less than 1 mSv. h-1 and at the surface less than 2 mSv.h-1. Storage containers must 
be fire resistant and carefully locked when in use to prevent access by unauthorized 
persons. The radiation symbols should be clearly visible on each container. A logbook must 
show the date of dispatch and the destination of the sources such as user’s address.  
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11. Conclusion 
The technique of permanent seed implantation in management of prostate carcinoma is 
historically proven and is being widely used in many advanced countries. Modern 
transrectal ultrasound-guided, interstitial permanent brachytherapy is a single outpatient 
treatment for the majority of men with early-stage prostate cancer. It has documented five- 
and ten-year biochemical, overall, and disease-specific relapse-free survival rates that equal 
the best that radical prostatectomy has thus far achieved. These favorable findings have 
established permanent prostate brachytherapy as a primary treatment option for early stage 
prostate cancer. 
The potential utility of various methods for the preparation of 125I-brachytherapy sources for 
prostate cancer have been documented. Quality control of 125I-brachytherapy sources after 
preparation is an important part. Many publications give recommendations on frequencies 
of quality control procedures without describing the procedures. It is, however, of extreme 
importance for the general process of quality assurance that these procedures are well 
defined and understood by the source manufactures. The quality control procedure 
depicted in this manuscript can be applied universally irrespective of the source preparation 
method adapted. The procedures presented here are a set of minimum requirements and 
can serve as guidelines for developing a QC protocol. It should be noted, however, that if 
any national set of requirements exists, these should be followed. It is envisaged that any 
one of the source preparation strategy would serve for ensuring easy availability 125I-
brachytherapy sources particularly in Institution with Radiochemistry Laboratory facility 
where commercial sources are too expensive. Availability 125I-brachytherapy sources at local 
level would promote the beneficial use of permanent seed implantation technique. 
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